1188417-09-5

Basic information

• Product Name: 1-methyl-2-[N-(4-cyanophenyl)aminomethyl]benzimidazole-5-ylcarboxylic acid N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide acetate salt
• Synonyms: 1-methyl-2-[N-(4-cyanophenyl)aminomethyl]benzimidazole-5-ylcarboxylic acid N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide acetate salt
• CAS NO: 1188417-09-5
• Molecular Weight: 542.594
• Mol File: 1188417-09-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-methyl-2-[N-(4-cyanophenyl)aminomethyl]benzimidazole-5-ylcarboxylic acid N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide acetate salt(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methyl-2-[N-(4-cyanophenyl)aminomethyl]benzimidazole-5-ylcarboxylic acid N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide acetate salt(1188417-09-5)
• EPA Substance Registry System: 1-methyl-2-[N-(4-cyanophenyl)aminomethyl]benzimidazole-5-ylcarboxylic acid N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide acetate salt(1188417-09-5)

Safety Data

• Hazardous Substances Data: 1188417-09-5(Hazardous Substances Data)

Upstream product

• 42288-26-6 (4-cyanophenyl)glycine 
• 64-19-7 acetic acid 
• 212322-56-0 ethyl 3-{[{2-amino-1-(methylamino)phen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 

Downstream Products

• 1223061-77-5 ethyl 3-[[[-2-[[(4-cyanophenyl)amino]phenyl]-1-methyl-1H-benzoimidazol-5-yl]carbonyl]pyridine-2-ylamino]propionate oxalate 
• 1354727-65-3 ethyl 3-[[2-[[ethoxy(imino)methylphenylamino]methyl]-1-methyl-1H-benzimidazole-5-carbonyl]pyridin-2-yl-amino]propionate hydrochloride 
• 211915-06-9 dabigatran etexilate 
• 429658-95-7 3-({2-[(4-carbamimidoylphenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester 
• 211915-84-3 3-[[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid ethyl ester 

Relevant articles and documents

IMPROVED PROCESSES FOR THE PREPARATION OF DABIGATRAN ETEXILATE USING NOVEL INTERMEDIATES

Disclosed herein are novel, commercially viable and industrially advantageous processes for the preparation of Dabigatran or a salt thereof, in high yield and purity, using novel intermediate compounds. The novel process solves the drawbacks associated with the prior processes and is commercially viable for preparing Dabigatran and its salts or derivatives thereof.